Specific Biologics announces oversubscribed US$35 million Series A financing
Specific Biologics announced the closing of an oversubscribed US$35 million Series A financing led by Hatteras Venture Partners, with participation from Lumira Ventures, adMare BioInnovations and other investors. The proceeds will be used to advance the lead Dualase therapeutic candidate through initial clinical biomarker proof-of-concept in the first cohort of an adaptive Phase I/II clinical trial in patients with C9ORF72-associated ALS.
Primary source
Company press release (PR Newswire), November 2, 2026
Specific Biologics Announces Oversubscribed US$35 Million Series A Financing to Advance Gene-Editing Therapy for ALS
Read the source: Specific Biologics Announces Oversubscribed US$35 Million Series A Financing to Advance Gene-Editing Therapy for ALS prnewswire.com
Machine-summarized from the source above; not independently reported. How we use automation